Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients.

ABSTRACT:

Background

Infliximab (IFX) is the first-line treatment for Crohn's disease (CD). However, the secondary loss of response (LOR) is common in IFX therapy. Therefore, non-invasive assessment of LOR in CD patients is the goal pursued by clinicians.

Methods

A multicenter study involving 181 CD patients was conducted, with patients being split into a training cohort (n = 102), testing cohort (n = 45), and validation cohort (n = 34). The study evaluated various clinical factors to establish a clinical model, and a radiomics signature was constructed based on reproducible features from computed tomography enterography (CTE). Logistic regression modeling was used to create models based on the radiomics signature and significant clinical factors, with the receiver operating character

SUBMITTER: Zhu C 

PROVIDER: S-EPMC10161257 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature